注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Arbutus Biopharma Corp是一家臨床階段的生物製藥公司。該公司專注於開發針對特定病毒疾病治療方法的病毒學能力。該公司的重點領域包括乙型肝炎病毒(HBV)、SARS-CoV-2和其他冠狀病毒。在HBV方面,該公司正在開發一種核糖核酸干擾(RNAi)治療劑、口服衣殼抑製劑、口服PD-L1抑製劑和口服RNA失穩劑,旨在通過抑制病毒複製、減少表面抗原和重新喚醒免疫系統,為慢性HBV感染(cHBV)患者提供功能性治療。其先導化合物AB-729是唯一具有免疫再覺醒證據的RNA干擾療法,目前正在多個II期臨床試驗中進行評估。該公司正在進行一項藥物研發計劃,旨在識別治療冠狀病毒(包括SARS-CoV-2)的口服活性藥物。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Frank M. Torti | 42 | 2018 | Independent Chairman of the Board of Directors |
Kyong-Mi Chang | - | - | Member of Scientific Advisory Board |
Ulrike Protzer | - | - | Member of Scientific Advisory Board |
Adrian Di Bisceglie | - | - | Member of Scientific Advisory Board |
Keith S. Manchester | 56 | 2015 | Independent Non-Executive Director |
William T. Symonds | 56 | 2015 | Chairman of Scientific Advisory Board |
Fabien Zoulim | - | - | Member of Scientific Advisory Board |
James R. Meyers | 59 | 2018 | Independent Director |
Daniel D. Burgess | 62 | 2017 | Independent Director |
Charles M. Rice | - | - | Member of Scientific Advisory Board |
Scott A. Biller | 68 | - | Member of Scientific Advisory Board |
Richard C. Henriques | 68 | 2014 | Independent Non-Executive Director |
Michael J. McElhaugh | 49 | 2018 | Co-Founder, Interim President, CEO & Director |
Melissa V. Rewolinski | 53 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核